Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 8/20 | 0.37 |
| ▸ | AURKA | O14965 | 6/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.37 |
| ▸ | SYK | P43405 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 6/20 | 0.35 |
| ▸ | JAK2 | O60674 | 5/20 | 0.35 |
| ▸ | TYK2 | P29597 | 4/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27241016 | 1.00 | CCNT1 (0.39) | CCNT1CCNE2CCNE1CDK2CDK9 | |
| SCHEMBL26977217 | 0.88 | JAK1 (0.43) | CCNT1CCNE2CCNE1CDK2CDK9 | |
| SCHEMBL29929159 | 0.86 | MAP4K1 (0.40) | JAK1AURKAAURKBSYKKDR | |
| SCHEMBL27240951 | 0.86 | MAP4K1 (0.40) | JAK1AURKAAURKBSYKKDR | |
| SCHEMBL26977031 | 0.86 | MAP4K1 (0.40) | JAK1AURKAAURKBSYKKDR | |
| SCHEMBL27124698 | 0.82 | JAK3 (0.48) | JAK1JAK3JAK2 | |
| SCHEMBL26980179 | 0.82 | JAK3 (0.48) | JAK1JAK3JAK2 | |
| SCHEMBL29113541 | 0.82 | JAK3 (0.40) | JAK1AURKAAURKBJAK3JAK2 | |
| SCHEMBL30931275 | 0.82 | JAK3 (0.48) | JAK1JAK3JAK2 | |
| SCHEMBL26979923 | 0.82 | JAK3 (0.48) | JAK1JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022182972-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | CCNT1 84/4885CCNE2 409/4885CCNE1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.